Volume 67, Issue 1, Pages (January 2015)

Slides:



Advertisements
Similar presentations
Volume 42, Issue 1, Pages 7-11 (July 2002)
Advertisements

Volume 50, Issue 3, Pages (September 2006)
Volume 45, Issue 5, Pages (May 2004)
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Medical Management for BPH: The Role of Combination Therapy
Volume 77, Issue 1, Pages (January 2011)
Dietary Antioxidants and Longitudinal Changes in Lower Urinary Tract Symptoms in Elderly Men: The Osteoporotic Fractures in Men Study  Kathleen F. Holton,
Volume 59, Issue 2, Pages (February 2011)
Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 72, Issue 5, Pages (November 2017)
Volume 68, Issue 3, Pages (September 2015)
Volume 191, Issue 3, Pages (March 2014)
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Volume 64, Issue 5, Pages (November 2013)
Volume 54, Issue 6, Pages (December 2008)
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Volume 62, Issue 5, Pages (November 2012)
Volume 73, Issue 1, Pages (January 2018)
Volume 65, Issue 1, Pages (January 2014)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Rowland Illing  European Urology Supplements 
Volume 70, Issue 5, Pages (November 2016)
Volume 59, Issue 2, Pages (February 2011)
Volume 55, Issue 2, Pages (February 2009)
The Long-Term Outcome of Medical Therapy for BPH
Volume 63, Issue 1, Pages (January 2013)
Volume 60, Issue 4, Pages (October 2011)
Back to the Future: Introduction and Conclusions
Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)  Raymond C. Rosen, Francois Giuliano, Culley.
Volume 51, Issue 1, Pages (January 2007)
Volume 52, Issue 3, Pages (September 2007)
Volume 56, Issue 3, Pages (September 2009)
Volume 60, Issue 4, Pages (October 2011)
Rowland Illing  European Urology Supplements 
Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen 
Volume 66, Issue 5, Pages (November 2014)
Volume 60, Issue 1, Pages (July 2011)
Volume 56, Issue 1, Pages (July 2009)
Volume 60, Issue 4, Pages (October 2011)
Volume 61, Issue 3, Pages (March 2012)
Volume 68, Issue 4, Pages (October 2015)
Volume 64, Issue 2, Pages (August 2013)
Yuanshan Cui, Yong Zhang  European Urology 
Rhythmic Working Memory Activation in the Human Hippocampus
Volume 71, Issue 4, Pages (April 2017)
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Classification of Male Lower Urinary Tract Symptoms Using Mathematical Modelling and a Regression Tree Algorithm of Noninvasive Near-Infrared Spectroscopy.
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 50, Issue 3, Pages (September 2006)
Volume 46, Issue 5, Pages (November 2004)
Volume 74, Issue 5, Pages (November 2018)
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Volume 54, Issue 6, Pages (December 2008)
Volume 53, Issue 6, Pages (June 2008)
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
C.G Roehrborn, T McNicholas  European Urology Supplements 
Classification of Mixed Incontinence
Volume 52, Issue 6, Pages (December 2007)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Primary outcome and patient reported secondary outcomes in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving.
End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy  Jeanette C. Reece,
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Presentation transcript:

Volume 67, Issue 1, Pages 114-122 (January 2015) Effect of Tadalafil on Male Lower Urinary Tract Symptoms: An Integrated Analysis of Storage and Voiding International Prostate Symptom Subscores from Four Randomised Controlled Trials  Christopher R. Chapple, Claus G. Roehrborn, Kevin McVary, Dapo Ilo, Carsten Henneges, Lars Viktrup  European Urology  Volume 67, Issue 1, Pages 114-122 (January 2015) DOI: 10.1016/j.eururo.2014.08.072 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Relationship between International Prostate Symptom Score (IPSS) storage and voiding subscores and total IPSS at baseline and after 12 wk of tadalafil treatment, as well as the change from baseline to 12 wk for all patients. Orange circles denote tadalafil and grey circles placebo. Circle size represents the number of patients. These plots highlight the constancy of the relationship between storage and voiding subscores before and after treatment with tadalafil. European Urology 2015 67, 114-122DOI: (10.1016/j.eururo.2014.08.072) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 (a) Relationship between the change from baseline to endpoint for total International Prostate Symptom Score (IPSS) and the S:T ratio at baseline in patients receiving tadalafil. The solid orange line depicts the standard 4:10 S:T ratio. Dark blue solid and dashed lines illustrate the modelling estimates with standard error for the change in total IPSS by S:T ratio. The optimal ratio corresponding to the greatest change in total IPSS is where the upper standard error intersects the zero-change line at 0.054 (5.4%) and 0.883 (88.3%). The S:T ratio corresponding to the maximum improvement in total IPSS is at 0.417 (41.7%). (b) Observed frequency of S:T ratios versus total IPSS at baseline in patients receiving tadalafil or placebo. The orange line denotes the margins at which the S:T ratio is either maximal or minimal for a given total IPSS. The colour density represents frequency: the red tone indicates higher density (ie, more subjects) than the blue tone; white indicates a frequency of zero. For higher IPSS, the range is densely covered and observations cluster between these margins. At the maximum IPSS (35), contributions from both storage and voiding subscores are also maximal. For lower total IPSS, the number of different permutations of storage and voiding subscores increases. Patients were eligible for enrolment in the study if they presented with a total IPSS ≥13 at baseline. During the placebo lead-in phase, treatment compliance was assessed via pill count, regardless of whether patients showed improvement. Therefore, this figure includes patients who responded to placebo during the placebo lead-in phase and had a total IPSS <13. S:T=ratio of storage IPSS subscore to total IPSS. European Urology 2015 67, 114-122DOI: (10.1016/j.eururo.2014.08.072) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Analysis of patients responding to tadalafil treatment in terms of the contribution of the storage subscore to the total International Prostate Symptom Score (IPSS) at the endpoint. Outcome by (a) S:T ratio and (b) response. The figures illustrate the lack of statistical association between the S:T ratio at baseline and the response to tadalafil (a), and between a high- versus low-degree of storage dysfunction at baseline and response to tadalafil (b). CI=confidence interval; OR=odds ratio; S:T=ratio of storage subscore to total IPSS. European Urology 2015 67, 114-122DOI: (10.1016/j.eururo.2014.08.072) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 4 Contribution of storage symptoms to total symptoms calculated as the mean change in IPSS from baseline following treatment with an alpha-blocker or tadalafil in men with LUTS/BPH according to published data. The dashed line indicates a 40% contribution of the storage subscore to total International Prostate Symptom Score (IPSS). The contribution of the storage subscore to total IPSS was calculated using published data; total IPSS is defined as the sum of storage and voiding subscores. BPH=benign prostatic hyperplasia; LUTS=lower urinary tract symptoms. European Urology 2015 67, 114-122DOI: (10.1016/j.eururo.2014.08.072) Copyright © 2014 European Association of Urology Terms and Conditions